Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-001 in advanced HER3 positive solid tumours
NCT05057013Phase 2Active, not recruiting
- Sponsor
- Cancer Research UK
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of hmbd-001 in solid tumor, prostate cancer (PCa), sponsored by Cancer Research UK. Started Nov 2021; status: active, not recruiting.
02
Drugs
hmbd-001
03
Conditions
solid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05057013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057013.